期刊
FRONTIERS IN PHARMACOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2021.772540
关键词
osteoclast; bone resorption; postmenopausal osteoporosis; bioinformatics; BCI
资金
- General project of Chongqing Natural Science Foundation of China [cstc2020jcyj-msxmX0688]
- National Key Research and Development Plan Project [2016YFC1101504]
- Clinical Research Project of the Second Affiliated Hospital of the Army Military Medical University [2018XLC2016]
BCI treatment attenuates osteoclast differentiation and alleviates osteoporosis by inhibiting STAT3 and NF-kappa B signaling pathways, suggesting a potential effective approach for treating osteoporosis.
Osteoporosis is a common aging-related metabolic disease that mainly occurs in older adults and postmenopausal women. Despite advances in anti-osteoporosis treatment, outcomes remain unsatisfactory due to detrimental side effects. BCI hydrochloride (BCI), a selective dual-specificity phosphatase 6 (DUSP6) inhibitor, is associated with multiple cellular functions, including inhibiting tumor growth and macrophage inflammation; however, its role in regulating osteoclast differentiation remains unknown. Here, we revealed that treatment with BCI attenuated RANKL-mediated osteoclast differentiation in vitro and alleviated ovariectomy-induced osteoporosis without obvious toxicity. Specifically, BCI disrupted F-actin ring formation and bone-resorption activity and decreased osteoclast-specific gene and protein levels in a dose-dependent manner. KEGG pathway analysis, GSEA based on transcriptome sequencing, and western blot results suggested that BCI inhibited RANKL-induced osteoclastogenesis by restraining STAT3 and NF-kappa B signaling and attenuating NF-kappa B/p65 interaction with NFATc1. These results revealed that BCI treatment prevented postmenopausal osteoporosis and might represent an effective approach for treating osteoporosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据